04 Aug 2010
Shire delivers excellent Q2 performance with total revenues up 35%. Full year earnings expectations raised.
August 4, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to June 30, 2010
|Financial Highlights||Q2 2010(1)|
|Product sales||$764 million||+37%|
|Product sales from core products(2)||$684 million||+39%|
|Product sales from core products on a CER basis(3)||+42%|
|Total revenues||$849 million||+35%|
|Non GAAP operating income||$270 million||+134%|
|US GAAP operating income||$224 million||+547%|
|Non GAAP diluted earnings per ADS||$1.03||+71%|
|US GAAP diluted earnings per ADS||$0.86||+253%|
(1) Percentages compare to equivalent 2009 period.
(2) Core products represent Shire’s products excluding ADDERALL XR.
(3) Sales growth at CER is computed by restating 2010 results using average 2009 foreign exchange rates.
Angus Russell, Chief Executive Officer, commented:
"This was another excellent quarter with strong performance from core product sales, up 39%, driving increases in operating income and earnings per ADS. Shire is performing well on all fronts.
In ADHD, sales of VYVANSE are up 30% and clinical trial enrolment has progressed for the European program and for the new indication proof of concept studies. Marketing authorization was recently given for VYVANSE in Brazil, our first approval for this product outside North America, and the launch is being planned for mid 2011. INTUNIV continues to build share with child and adolescent psychiatrists and we recently filed an sNDA for its adjunctive use with long-acting oral stimulants for the treatment of ADHD.
Sales of our Fabry treatment, REPLAGAL are up 84%, and we’ve seen very rapid uptake of VPRIV in the Gaucher market place with approximately 850 patients now treated globally. We received a positive opinion for VPRIV from the Committee for Medicinal Products for Human Use and although we already have sales on a preapproved basis, the anticipated European Commission decision later this year will enable the product’s commercial roll out.
LIALDA for ulcerative colitis is also performing well with sales up 27% and a US market share approaching 19%. Phase 3 clinical trials investigating the use of the product for the treatment of diverticular disease are progressing.
With cash generation of $416 million during the quarter and excellent growth prospects ahead, we continue to invest in our marketed products, our pipeline and our international presence.
This year, the pharmaceutical sector has faced the challenges of US healthcare reform, European pricing pressures and fluctuating foreign exchange levels. Shire is, however, well placed to absorb these macro factors. Our strong performance in the second quarter reinforces our confidence in growing both revenue and earnings in the full year 2010 compared to 2009 and we now see Non GAAP earnings trending towards $4.00 per ADS for the full year. This includes the financial effect of the proposed acquisition of Movetis NV. We also re-iterate our aspirational target of mid-teens sales growth on average between 2009 and 2015."